On February 16, 2022, FDA published a compounding threat warn describing the probable pitfalls connected to at-residence use of compounded ketamine nasal spray and several adverse function reviews. The February 2022 compounding possibility alert also furnished details about Spravato, that is subject to a Hazard Evaluation and Mitigation Tactic (REM